Stoke Therapeutics prices $125M public offering of common stock and pre-funded warrants

Stoke Therapeutics, Inc.

Priced 5,555,557 shares at $13.50/share and pre-funded warrants for 3,703,730 shares at $13.4999.
Expected gross proceeds of $125M; net proceeds ~$119.8M after underwriting discounts and expenses.
Net proceeds to fund research, clinical development of STK-001 and STK-002, and other corporate purposes.
Offering expected to close on April 2, 2024; J.P. Morgan acting as sole book-running manager.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Stoke Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC valued at approximately $119.8 million (effective 2024-03-27).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC
Value: approximately $119.8 million
Effective: 2024-03-27

Exact text from the filing

On March 27, 2024, Stoke Therapeutics, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC as representative of the underwriters named therein (the “Underwriter”), pursuant to which the Company agreed to issue and sell 5,555,557 shares (the “Underwritten Shares”) of its common stock, par value $0.0001 per share (“Common Stock”) to the Underwriter in a public offering at a price of $13.50 per Underwritten Share

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-080874

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.